Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

ROCKVILLE, Md., Oct. 8, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company's ...

Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced ...

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and ...

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- The "CRISPR Technology Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio ...

Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE. ・The partnership aims to advance an off-the-shelf LVV Plasmid DNA platform ...

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...